Cystic fibrosis precision therapeutics: Emerging considerations
Sign Up to like & getrecommendations! Published in 2019 at "Pediatric Pulmonology"
DOI: 10.1002/ppul.24547
Abstract: Small molecules that address fundamental defects underlying cystic fibrosis (CF), including modulators such as the approved drugs ivacaftor, lumacaftor, tezacaftor, and elexacaftor, have advanced dramatically over the past few years and are transforming care and… read more here.
Keywords: cystic fibrosis; fibrosis; therapeutics emerging; precision therapeutics ... See more keywords